Table III.
Serum Calcium Lowering Effect of sCT and Mono/di-bio sCTs Following Intrajejunal or Intravenous Administration at Doses of 100 μg and 1 μg in Rats Respectively (mean ± SD, n = 3, ANOVA/LSD Post-hoc, p < 0.05)
| Treatment | Time to maximum decrease in serum Ca (h) | % maxd in serum Ca | D% in 1 and 7 h for iv and ij application respectively |
|---|---|---|---|
| sCT (iv) | 1 | 12.2 ± 1.3 | 11.4 ± 1.8 |
| Lys11-mono-bio-sCT (iv) | 1 | 17.7 ± 1.7 | 14.5 ± 1.6 |
| Lys11,18-di-bio-sCT (iv) | 1 | 18.2 ± 2.2 | 13.6 ± 1.9 |
| sCT (ij) | 2 | 12.9 ± 2.3 | 11.4 ± 2.6 |
| Lys11-mono-bio-sCT (ij) | 4 | 21.6 ± 2.1 | 19.3 ± 1.9 |
| Lys11,18-di-bio-sCT (ij) | 6 | 30 ± 2.5 | 28.6 ± 2.0 |